Navigation Links
GEN reports on recent progress in Alzheimer's research
Date:8/7/2012

New Rochelle, NY, August 7, 2012The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN.

"Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer's," said John Sterling, Editor-in-Chief of GEN. "Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly."

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of -amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lilly, GE Healthcare Life Sciences, and Charles River Laboratories.


'/>"/>

Contact: John Sterling
jsterling@genengnews.com
914-740-2196
Mary Ann Liebert, Inc./Genetic Engineering News
Source:Eurekalert  

Related biology news :

1. BGI reports the latest finding on NMNAT1 mutations linked to Leber congenital amaurosis
2. Aware, Inc. Reports Second Quarter 2012 Financial Results
3. GEN reports on growth of tissue engineering revenues
4. BGI reports the completed sequence of foxtail millet genome
5. Radiologists study necessity of additional imaging recommendations in PET/CT oncologic reports
6. Aware, Inc. Reports First Quarter 2012 Financial Results
7. From 503-million-year-old fungi to recent earthquakes: New Geology posted ahead of print
8. House funding bill will delay research progress and place new burdens on NIH
9. Guam conservation efforts progress
10. New report evaluates progress of Everglades Restoration Plan
11. Progress in Osteoporosis re-launched with new design, now invites commentary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
GEN reports on recent progress in Alzheimer's research
(Date:1/27/2020)... ... January 27, 2020 , ... Cytonus Therapeutics Inc. today announced ... entrepreneur, and former senior management consultant at McKinsey & Company who holds three ... investment firm. , “Chris Thorne has exceptional business acumen with a proven ...
(Date:1/23/2020)... ... January 23, 2020 , ... GIOSTAR/HEAMGEN has ... stem cells. The red blood cells are made utilizing a bioreactor that ... transfusion therapy and replaces the need for a human blood donor. ...
(Date:1/10/2020)... , ... January 09, 2020 , ... ... bioactive spinal solutions, today announced the 510(K) clearance and commercial launch of the ... interbody fusion system. , The EVOL®ha-DLIF is made of PEEK-OPTIMA HA Enhanced ...
Breaking Biology News(10 mins):
(Date:2/11/2020)... ... February 11, 2020 , ... ... services in North America, today announced that the City of Fort Worth has ... biosolids management needs. Commencing in April of 2020, Synagro will assume operation of ...
(Date:2/3/2020)... ... February 03, 2020 , ... ... MA, announce that OmniType, the 11-locus, single tube multiplex successor to Holotype HLA ... best-in-class product featuring locus-multiplexing and short library preparation, for HLA genotyping from sample ...
(Date:1/27/2020)... , ... January 27, 2020 , ... ... it has secured financing from strategic investors led by Halma plc , ... existing investors Sonion, TDF Ventures, GII LLC, and WSJ Joshua Fund. A representative ...
(Date:1/22/2020)... ... January 20, 2020 , ... Brilliant, maker of the ... largest independent electronics distributor in the US, to make it easy for homebuilders, ... leading smart home products from a single fulfillment partner. Ranging from entry-level systems ...
Breaking Biology Technology: